Indication
Liver Metastases
52 clinical trials
56 products
21 drugs
Clinical trial
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard TherapyStatus: Completed, Estimated PCD: 2023-01-13
Product
STP705Product
DNX-2440Clinical trial
A Phase I Safety and Window-of-opportunity Study of Preoperative Intratumoral Injection of OX40-ligand Expressing Oncolytic Adenovirus (DNX-2440) in Patients With Resectable Liver MetastasisStatus: , Estimated PCD: 2026-07-31
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid TumorsStatus: Terminated, Estimated PCD: 2023-05-31
Product
MIV-818Clinical trial
A Phase 1/2a Study in 3 Parts to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients With Liver Cancer ManifestationsStatus: Active (not recruiting), Estimated PCD: 2024-02-29
Product
ONCR-177Product
pembrolizumabProduct
Talimogene LaherparepvecClinical trial
A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab to Treat Subjects With Advanced Solid Tumors in Phase 2 (MASTERKEY-318)Status: Completed, Estimated PCD: 2022-02-14
Product
PembrolizumabProduct
CVA21Product
IpilimumabClinical trial
An Open-Label Phase 1b Clinical Study of Intravenous CAVATAK® (Coxsackievirus A21, CVA21), in Combination With Ipilimumab in Subjects With Uveal Melanoma Metastatic to Liver (VLA-024 CLEVER)Status: Completed, Estimated PCD: 2019-05-22
Clinical trial
A First In Human, Open Label, Dose Escalation Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Clinical Activity Profile Of Single Agent RO7119929 (TLR7 Agonist) Administered Orally To Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic MetastasesStatus: Completed, Estimated PCD: 2023-01-09
Product
RO7119929Product
TocilizumabClinical trial
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence: A Randomized Controlled Phase II TrialStatus: Recruiting, Estimated PCD: 2025-09-25
Drug
CisplatinDrug
PD-1 antibodyClinical trial
Phase II Study of Isolated Hepatic Perfusion With Melphalan Followed By Postoperative Hepatic Arterial Chemotherapy in Patients With Unresectable Colorectal Cancer Metastatic to the LiverStatus: Completed
Product
floxuridineProduct
LeucovorinProduct
melphalanClinical trial
Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Capecitabine in Patient With Non-resectable Liver Metastases From Breast Cancer A Phase II Trial in Patients With Limited Extrahepatic DiseaseStatus: Completed, Estimated PCD: 2017-05-01
Product
OxaliplatinClinical trial
An Open-Label Pilot Study to Evaluate Efficacy and Safety of Bevacizumab Via Transarterial Chemoembolization (TACE) in Patients With Liver MetastasesStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Drug
AtezolizumabClinical trial
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver MetastasesStatus: Recruiting, Estimated PCD: 2025-09-01
Drug
BotensilimabProduct
BalstilimabProduct
AGEN1423Clinical trial
SCANDIUM II Trial - A Phase I Randomized Controlled Multicentre Trial of Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma MetastasesStatus: Active (not recruiting), Estimated PCD: 2024-08-04
Clinical trial
Adjuvant Systemic Chemotherapy With or Without Hepatic Arterial Infusion Using Floxuridine in Patients Following Colorectal Cancer Liver Metastases ResectionStatus: Terminated, Estimated PCD: 2021-08-31
Clinical trial
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The LiverStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Product
Drug Eluting BeadsProduct
NivolumabProduct
FUDRDrug
FOLFOXIRIDrug
5-FUDrug
IrinotecanClinical trial
Risk-Stratified Adjuvant Therapy: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver MetastasesStatus: Recruiting, Estimated PCD: 2026-02-28
Product
5-FLUOROURACILProduct
CapecitabineProduct
BevacizumabClinical trial
French Assessment of Minimal Residual Disease by Liquid Biopsies in Colorectal With Liver Metastasis PatientsStatus: Not yet recruiting, Estimated PCD: 2025-10-31
Product
Blood sampleClinical trial
A Phase 2 Study Using Stereotactic Ablative Radiation Therapy and Ipilimumab in Patients With Oligometastatic MelanomaStatus: Completed, Estimated PCD: 2020-08-03
Drug
ipilimumabClinical trial
A Randomized Clinical Trial Comparing Overall Survival in Selected Patients With ColoRectal Carcinoma Treated by Liver Transplantation or ChemotherapyStatus: Recruiting, Estimated PCD: 2027-01-01
Drug
DocetaxelClinical trial
Combination of Regorafenib，Toripalimab and Celecoxib in Mismatch Repair (MMR) Proficient Refractory Advanced Colorectal Cancer Without Liver Metastasis：a Single Arm Phase II REGOTORICOX Study.Status: Recruiting, Estimated PCD: 2025-09-20
Product
Rego+Tori+CeleClinical trial
Neoadjuvant Combination of Serplulimab and Bevacizumab With FOLFOX Versus FOLFOX Alone for Resectable Liver Metastases in RAS/BRAF Wild-Type, pMMR/MSS Colorectal Cancer PatientsStatus: Recruiting, Estimated PCD: 2026-12-31
Drug
mFOLFOX6Product
SerplulimabClinical trial
Acetylsalicylic Acid as Secondary Prevention in Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2022-02-01
Drug
AspirinClinical trial
Hepatic Arterial Infusion Chemotherapy Combined Sintilimab for Predominant Liver Metastasis From Esophageal Squamous Cell Carcinoma- A Pilot StudyStatus: Completed, Estimated PCD: 2023-10-18
Clinical trial
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the LiverStatus: Recruiting, Estimated PCD: 2029-12-31
Product
PanitumumabProduct
FUDR-DexDrug
cetuximabClinical trial
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX in Patients With Initially Unresectable Colorectal Liver MetastasisStatus: Active (not recruiting), Estimated PCD: 2022-12-30
Drug
mFOLFOXIRIProduct
CetuximabDrug
fluorouracilProduct
PlaceboClinical trial
Adaptive Stereotactic Radiotherapy With Superparamagnetic Iron Oxide Nanoparticles (SPION) Cellular Magnetic Resonance Imaging on MR-Linac (MR-L-SPION) for Primary and Metastatic Hepatic Malignancies With Assessment of Treatment Response.Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
FerumoxytolClinical trial
Pre-and Post-operative Cetuximab Plus mFOLFOX6 Versus mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable Colorectal Liver MetastasesStatus: Not yet recruiting, Estimated PCD: 2026-07-15
Product
mFOLFOX6 + CetuximabDrug
mFOLFOX 6Clinical trial
EXtended CriteriA Treatment for LIver Metastases With Heavy Tumour BURden 1 + 2Status: Recruiting, Estimated PCD: 2024-05-01
Product
FloxuridineClinical trial
Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency AblationStatus: Withdrawn, Estimated PCD: 2021-06-01
Clinical trial
Immunotherapy Combined With Yttrium-90 RadioEmbolization in the Treatment of Colorectal Cancer With Liver Metastases [iRE-C - Clinical Trial]Status: , Estimated PCD: 2023-12-31
Drug
AN0025Clinical trial
A Pilot Study of 64Cu-DOTA-Trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab EmtansineStatus: Active (not recruiting), Estimated PCD: 2021-12-07
Product
trastuzumabProduct
Ado-Trastuzumab EmtansineClinical trial
An Open Label, Single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) Vaccine and Anti-PD1 (Nivolumab) as Adjuvant Treatment in Resected Hepatocellular Carcinoma (HCC) (Group A) and Liver Metastases From Colorectal Cancer (CRLM) (Group B)Status: Recruiting, Estimated PCD: 2025-05-01
Drug
T-VECClinical trial
PET Imaging of Hepatocellular Carcinoma With 18F-FSPGStatus: Recruiting, Estimated PCD: 2025-05-31
Product
Carbon C 11 AcetateClinical trial
Low Dose ICG for Near-infrared Fluorescence Imaging of Biliary Tract and TumorsStatus: Completed, Estimated PCD: 2022-09-15
Product
Indocyanine greenClinical trial
IIT2022-05-Sankar-BELIEVE: Phase II Study of Bevacizumab in Combination With Chemoimmunotherapy and Maintenance Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver MetastasesStatus: Not yet recruiting, Estimated PCD: 2026-09-28
Clinical trial
A Phase II Trial of Hepatic Artery Infusional Floxuridine With Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver MetastasesStatus: Recruiting, Estimated PCD: 2026-04-01
Product
Heparinized SalineClinical trial
Evaluation of Liver MR With an Abbreviated Gadobenate Dimeglumine Hepatobiliary Phase Protocol in Comparison to Liver MR With Gadoxetate Disodium for the Detection of Hepatic MetastasesStatus: Recruiting, Estimated PCD: 2024-08-09
Product
Gadoxetate disodiumProduct
Gadobenate dimeglumineClinical trial
A Prospective Study of Hyperthermia Combined With Autologous Adoptive Cellular Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or MetastasesStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)Status: Active (not recruiting), Estimated PCD: 2023-06-13
Drug
LurbinectedinClinical trial
COLLISION RELAPSE Trial - Recurrent Colorectal Liver Metastases: Repeat Local Treatment +/- Neoadjuvant Systemic Therapy - a Phase III Prospective Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2027-05-01
Product
Neoadjuvant systemic therapyClinical trial
Serplulimab in Combination With Regorafenib and Hepatic Artery Bicarbonate Infusion for Third-line Treatment in Patients With Colorectal Cancer and Liver Metastases: a Single-center, Single-arm, Phase 2 TrialStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Product
Serplulimab+RegorafenibClinical trial
Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation: a Prospective Parallel TrialStatus: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA: a Multicenter, Randomized, Controlled, Phase III Clinical Trial.Status: Recruiting, Estimated PCD: 2029-02-20
Product
FOLFOXDrug
UTD1Clinical trial
rRp450-Phase I Trial in Liver Metastases and Primary Liver TumorsStatus: Active (not recruiting), Estimated PCD: 2026-07-01
Product
rRp450Clinical trial
A Phase II Study of Perioperative QBECO Site Specific Immunomodulator (Qu Biologics®) in Patients With Metastatic Colorectal Adenocarcinoma Within the Liver Undergoing ResectionStatus: Recruiting, Estimated PCD: 2025-02-01
Product
QBECODrug
VarlilumabClinical trial
A Prospective, Single-arm Study on the Efficacy and Safety of Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant MelanomaStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the LiverStatus: Terminated, Estimated PCD: 2017-07-19
Drug
everolimusClinical trial
ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer: A Prospective Multicenter Randomized Controlled Clinical TrialStatus: Recruiting, Estimated PCD: 2031-02-20
Clinical trial
An Exploratory Study of Tislelizumab in Combination With Oxaliplatin and Tegafur for the Treatment of Gastric Cancer With Liver MetastasesStatus: Recruiting, Estimated PCD: 2025-08-31
Product
TislelizumabClinical trial
FUDR/Oxaliplatin HAI Plus Irinotecan Chemotherapy vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLMStatus: Terminated, Estimated PCD: 2022-10-31
Clinical trial
Intravenous Lidocaine for Postoperative Recovery in Liver Surgery, a Randomized Double Blinded Placebo-controlled StudyStatus: Recruiting, Estimated PCD: 2025-12-31
Product
LidocaineClinical trial
Combination Treatment of Nivolumab, Ipilimumab, Intratumoral CMP-001 and Radiosurgery for Liver Metastases in Colorectal CarcinomaStatus: Completed, Estimated PCD: 2021-08-18
Product
CMP-001